Deep venous thrombosis after high-dose intravenous immunoglobulin in the treatment of pemphigus vulgaris

Cutis

Volumn 73, Issue 6, 2004, Pages 403-406

  Sheehan, Daniel J ^a   Lesher Jr , Jack L ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; WARFARIN;

ADOLESCENT; CHILL; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; HEART INFARCTION; HUMAN; MALE; PEMPHIGUS VULGARIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

ADULT; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PEMPHIGUS; VENOUS THROMBOSIS;

EID: 3042566866     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol. 2001;44:1010-1024.
2. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology. 1994;44:1180-1181.
3. Crouch ED, Watson LE. Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura: a case report and literature review. Angiology. 2002;53:113-117.
4. Katz KA, Hivnor CM, Geist DE, et al. Stroke and deep venous thrombosis complicating intravenous immunoglobulin infusions. Arch Dermatol. 2003;139:991-993.
5. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:679-690.
6. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47:358-363.
7. Sami N, Qureshi A, Ruocco E, et al. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol. 2002;138:1158-1162.
8. Evangelou N, Littlewood T, Anslow P, et al. Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003;56:308-309.
9. Klaesson S, Ringden O, Ljungman P, et al. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in venoocclusive disease of the liver? Transplantation. 1995;60:1225-1230.
10. Steinberger B, Coleman TA. Multiple complications of IVIg therapy in a patient with Guillain-Barre sydrome. Am J Hematol. 2001;67:59.
11. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.
12. Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood. 2000;95:1856-1861.
13. Stangel M, Muller M, Marx P. Adverse events during treatment with high-dose intravenous immunoglobulin for neurological disorders. Eur Neurol. 1998;40:173-174.
14. Haplea SS, Farrar JT, Gibson GA, et al. Thromboembolic events associated with intravenous immunoglobulin therapy [abstract]. Neurology. March 1997; 48(suppl):A54.
15. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy. 2002;22:1638-1641.